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Dmore than 4300 peptide cleavage sites, spanning both the prime
and non-prime sides of the scissile peptide bond allowing detailed
subsite cooperativity analysis. The proteomic cleavage data were
expanded by kinetic analysis using a set of 6 quenched-ﬂuorescent
peptide substrates designed using these results. These datasets
represent one of the largest speciﬁcity proﬁling efforts with sub-
sequent structural follow up for any protease family and put the
spotlight on the speciﬁcity similarities and differences of the MMP
family. A detailed analysis of this data may be found in Eckhard
et al. (2015) [1]. The raw mass spectrometry data and the corre-
sponding metadata have been deposited in PRIDE/Proteo-
meXchange with the accession number PXD002265.
& 2016 The Authors. Published by Elsevier Inc. This is an open
access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Speciﬁcations Tableubject area Biology
ore speciﬁc sub-
ject areaProteolytic enzymes, metalloproteinases, substrate speciﬁcity proﬁling,
inhibitor design, drug discovery, matrix biology, extra cellular matrix (ECM).ype of data Mass spectrometry raw-ﬁles; search engine output ﬁles; metadata; quen-
ched ﬂuorescent peptide cleavage data; speciﬁcity proﬁling analysis (.xlsx).ow data was
acquiredLiquid chromatography tandem mass spectrometry (LC-MS/MS): either
QSTAR XL or QSTAR Pulsar I (Applied Biosystems) mass spectrometer cou-
pled on-line to LC Packings capillary LC system (Dionex).ata format RAW ﬁles: .wiff and .mzXML-ﬁles; .tandem and .pepxml post-database
search output ﬁles from X! Tandem [2].xperimental
factors(A) Human MMPs 1, 2, 3, 8, 9 and 13 were expressed and puriﬁed from CHO
or Timp2 / MEF-conditioned medium [3–7]. Soluble MMP14 (A21-R513)
was puriﬁed from Pichia pastoris [3]. MMP7 was purchased from Enzo Life
Sciences and MMP12 was a kind gift from Novartis. ProMMP3 was activated
using chymotrypsin; all other proMMPs were activated using APMA. (B)
Proteome-derived peptide libraries were prepared from K562 cells in the
presence of protease inhibitors [8,9]. Proteins were denatured and cysteine
side-chains alkylated. After reaction clean-up, proteomes were digested with
trypsin or GluC giving orthogonal peptide libraries. Primary amines were
dimethylated, peptide libraries puriﬁed, and stored as 200 mg aliquots at
80 °C.xperimental
featuresPICS cleavage assays [8,9] were performed by incubating peptide libraries
with MMP. Cleaved peptides with neo-N-termini were biotinylated and
afﬁnity puriﬁed. Eluates were desalted and analyzed by LC–MS/MS. Spectra
were matched to peptides using X! Tandem [2] and statistically evaluated
with PeptideProphet [10,11]. Identiﬁed peptides represent prime-side clea-
vage products and complete cleavage sites were reconstructed using Web-
PICS [12].ata source
locationOverall Laboratory, Centre for Blood Research, Department of Oral Biological
and Medical Sciences, Faculty of Dentistry, University of British Columbia,
Vancouver, BC, Canada. 49 °15044.5″N 123 °14041.8″W.ata accessibility The mass spectrometry raw data have been deposited in PRIDE/Proteo-
meXchange with the accession number PXD002265.
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 Comprehensive speciﬁcity proﬁling data of nine matrix metalloproteinases using PICS proteomics.
 Largest compendium of matrix metalloproteinase P6–P60 cleavage sites, reporting more than 4300
cleaved peptides.
 Identiﬁed cleavage sites allow in-depth cooperativity analysis of speciﬁcity subsites.
 Quenched ﬂuorescent peptide cleavage data corroborating the speciﬁcity proﬁles.
 These data can guide small molecule drug development and help in discrimination between direct
and indirect MMP targets.1. Data
Matrix metalloproteinases (MMPs) regulate the structural matrix environment and extracellular
signaling by precise proteolytic cleavage. Unraveling complex in vivo proteolytic networks is chal-
lenging. Thus comprehensive speciﬁcity proﬁles of all proteases involved are needed to guide
interpretation.
The data in the ProteomeXchange archive (PXD002265) and accompanying data of the present
article provide a comprehensive resource for the individual assessment of the active site speciﬁcity of
nine representative members of the human matrix metalloproteinase (MMP) family. The in-depth
speciﬁcity comparison based on these proteomic data corroborated with kinetic analysis using a set of
6 quenched ﬂuorescent peptides and in silico peptide docking was presented recently [1].
MMPs 1, 2, 3, 7, 8, 9, 12, 13 and 14 were all assayed by the high-throughput Proteomic Identiﬁ-
cation of protease Cleavage Sites (PICS; or PICS proteomics) method [8,9] and using two orthogonal
human whole-proteome peptide libraries (generated with trypsin or GluC). These data were analyzed
using X! Tandem [2] for peptide-spectrum matching, and PeptideProphet [11] for statistical evalua-
tion. However, other search engines such as Mascot [13], MS-GFþ [14], Comet [15], or MS Amanda
[16] can be used to extend the number of matched spectra by combining the results using e.g.
iProphet [17] within the Trans Proteomic Pipeline [10] or PeptideShaker [18]. Here we provide
additional data to enable other researchers to (i) reinvestigate our analysis to identify additional
subsite cooperativity effects and so far unexplored speciﬁcity preferences, and (ii) reanalyze our raw-
data with entirely new concepts or ideas in mind, such as speciﬁcity-oriented protease evolution
[19,20], functional phylogeny [21], or substrate-driven mapping of the degradome [22].
A representative PICS workﬂow is depicted in Fig. 1, and a graphical representation of the various
MMP domain architectures is shown in Supplementary Fig S1. Speciﬁcity proﬁling results were
summarized as heat maps in Figs. 2 and 3 (trypsin generated libraries) and Supplementary Figs 2 and
3 (GluC-generated libraries). Supplementary Table S1 provides a general resource for the MMPs
analyzed, giving their domain boundaries and links to the major databases in protein and protease
research: UniProt [23], Pfam [24], MEROPS [25], and TopFIND [26–28]. Supplementary Table S2
depicts key residues and all secondary structure elements characterizing the different MMP catalytic
domains, and shows a structural overlay of all analyzed MMPs. Supplementary Tables 3 and 4 contain
the individual MMP speciﬁcity proﬁling results obtained from trypsin- and Glu-generated peptide
libraries, respectively. Identiﬁed thioacylated prime-side cleavage products (column A), the WebPICS
[12] results (columns C–I) including HeatMaps (www.gnuplot.info) and iceLogos [29], and the indi-
vidual subsite analysis (columns K–W) together with the amino acid distribution in the human
proteome (UniProt release 2013_10) used for calculating normalized abundances (columns Y–AA) are
shown. Additionally, a high resolution PICS workﬂow is shown on both index pages, and all original
WebPICS results are provided in the supplement as a combined zip-ﬁle. Supplementary Table S5
provides the data matrices underlying our subsite cooperativity analysis, in which we ﬁxed certain
subsites (e.g. P3-Pro or P10-Leu) and analyzed the changes of the individual amino acid occurrences in
the other subsites (P6–P60). Supplementary Table S6 provides the raw data of our quenched ﬂuor-
escent cleavage assays, including a graphical representation of two of the peptides (PLG↓L and PAN↓L)
and a high resolution table summarizing the results normalized to the standard MMP substrate PLG↓L
(originally referred to as QF-24) [30]. Detailed database search settings for PICS data analysis are given
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Fig. 1. Proteomic Identiﬁcation of protease Cleavage Sites (PICS) workﬂow. PICS libraries are generated from cellular pro-
teomes, e.g. human cell cultures, and thus represent biological sequence diversity. Speciﬁc endoproteases such as trypsin, GluC,
or chymotrypsin are then used to digest proteomes into peptides amenable for mass spectrometry. Primary amines and thiols
are chemically protected and the peptide library is puriﬁed. Next, the proteome-derived peptide library is incubated with the
endoprotease of interest (e.g. MMP1). Prime side cleavage products (i.e. peptide fragments C-terminal of the cleavage site
depicted between P1 and P10) possess free and thus reactive N-termini that are subsequently tagged with cleavable biotin
allowing speciﬁc isolation with immobilized streptavidin. Following elution, prime-side cleavage products are identiﬁed by LC–
MS/MS, and the corresponding non-prime sequences are reconstructed bioinformatically, e.g. by using the free webservice
WebPICS (http://clipserve.clip.ubc.ca/pics/) [12].
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Fig. 2. Sequence speciﬁcity proﬁles of MMPs 1, 2, 3, 7, 8, 9, 12, 13, and 14 using trypsin-generated human peptide libraries.
Identiﬁed cleavage sites are summarized as heat maps showing relative amino acid occurrence. P6–P60 subsite positions are
shown on the x axes with the identiﬁed cleavage site between P1 and P10 . Plotted amino acids are indicated on the y axes with
single-letter codes. Please refer to Supplementary Fig S2 for corresponding results using GluC-generated peptide libraries.
U. Eckhard et al. / Data in Brief 7 (2016) 299–310 303in Supplementary Table S7. Additionally, a combined zip-ﬁle of all WebPICS results can be found in
the supplement. All mass spectrometry raw data and corresponding metadata have been deposited in
the ProteomeXchange Consortium database (http://proteomecentral.proteomexchange.org) via the
PRIDE partner repository [51] with the PXD identiﬁer /PXD002265S.
We previously used PICS to characterize a wide selection of different proteases, such as clostridial
collagenases [31], plant metalloproteinases [32], human type II transmembrane serine proteases
(TTSPs) [33], the archaeal protease LysargiNase [34], snake venom serine proteinases [35], human
coagulation factor Xa [12], and caspases 3 and 7 [8], proving both its versatility and robustness.
Importantly, PICS is designed for active site speciﬁcity proﬁling and not for the identiﬁcation of native
substrates. For the latter task, the Overall lab developed TAILS (Terminal Amine Isotopic Labeling of
Substrates) [36,37], which we have successfully used e.g. for the identiﬁcation of natural substrates of
dipeptidyl peptidases 8 and 9 [38], the human gelatinases MMP2 and 9 [39], membrane-type 6 matrix
metalloprotease MMP25 [40] and the meprins [41]. Over the last few years we have adapted TAILS for
the study of complex in vivo biological systems [42] and identiﬁcation of N-terminal modiﬁcations
such as proteolytic processing that alter protein stability or function [43,44]. We have assessed the N-
terminome of various tissues and cells, such as skin [42], erythrocytes [43], platelets [45], and dental
Fig. 3. MMP sequence speciﬁcity proﬁles identiﬁed in trypsin-generated human peptide libraries and summarized as heat
maps showing fold-change over natural abundance. P6–P60 subsite positions are shown on the x axes with the identiﬁed
cleavage site between P1 and P10 . Plotted amino acids are indicated on the y axes with single-letter codes. Please refer to
Supplementary Fig S3 for corresponding results using GluC-generated peptide libraries.
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ization of any biological system and protease in an unbiased, proteomics-centered manner.
The following materials and methods section will enable other investigators and laboratories to
design similar experimental procedures to study matrix metalloproteinases or any other protease by
PICS proteomics. Please refer to our recent dental pulp proteomics and N-terminomics Data in Brief
article for more information on TAILS [47].2. Experimental design, materials and methods
2.1. Expression and puriﬁcation of human MMPs
2.1.1. Summary
MMPs 1, 2, 3, 8, 9 and 13 were expressed as zymogens using the pGW1HG vector (kindly provided
by British Biotech Pharmaceuticals, Oxford, UK), and puriﬁed from serum-free conditioned medium
from (i) Chinese hamster ovary (CHO) cells or (ii) murine embryonic Timp2 / ﬁbroblasts (MEFs) [3–
7]. Soluble MMP14 lacking the C-terminal transmembrane and cytoplasmic domain (A21-R513) was
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ﬂash-frozen with liquid nitrogen, and stored at 70 °C until use. For more expression and puriﬁca-
tion details, see below. Active MMP7 was purchased from Enzo Life Sciences, and MMP12 was a kind
gift from Novartis Pharma AG (Basel, CH). ProMMP3 was activated using chymotrypsin. All others
proMMPs were activated using APMA.
2.1.2. ProMMP1
Chinese hamster ovary (CHO-K1) cells (American Type Culture Collection) were maintained in
Dulbecco's modiﬁed Eagle's medium (Invitrogen) supplemented with 10% cosmic calf serum (HyClone
Laboratories, Inc.) and non-essential amino acids (Invitrogen). Cells were transfected with pGW1HG-
MMP1 and selected with 25 μg/ml mycophenolic acid (Invitrogen). MMP1-expressing clones were
expanded to conﬂuence in roller bottles (850 cm2, BD Biosciences), washed with phosphate-buffered
saline (PBS; 138 mm NaCl, 2.7 mm KCl, 20 mm Na2HPO4, 1.5 mm KH2PO4, pH 7.4), and incubated in
100 ml of serum-free CHO-S-SFM II medium (Invitrogen). Conditioned serum-free medium was col-
lected every 1–2 days for up to 8 days. ProMMP1 was puriﬁed from collected culture supernatants
using an (i) Orange-Sepharose column equilibrated in MES buffer (50 mM MES, pH 6.0, 5 mm CaCl2,
0.1 M NaCl, 0.025% sodium azide), and eluted with 1 M NaCl (in MES buffer). Elution fractions were
subsequently loaded on (ii) Zn2þ-chelating Sepharose Fast Flow resin (Amersham Biosciences), and
chromatographed with a linear imidazole gradient (0 to 0.5 M). Fractions containing proMMP1 were
pooled and dialyzed into HEPES buffer (50 mM HEPES pH 7.2, 5 mM CaCl2, 0.1 M NaCl).
2.1.3. ProMMP2
TIMP-2-free human proMMP2 was expressed in ras/myc-transformed Timp2/ ﬁbroblasts. Cells
were grown in Dulbecco's modiﬁed Eagle's medium with 10% cosmic calf serum (HyClone Labora-
tories Inc), transfected with MMP2-pGW1HG, and selected by using 25 μg/ml mycophenolic acid.
Serum-free conditioned mediumwas harvested from roller bottles and proMMP2 was puriﬁed at 4 °C
in MES buffer by (i) gelatin-Sepharose (Amersham Biosciences) chromatography. After elution with
10% dimethyl sulfoxide in HEPES buffer, samples were dialyzed into MES buffer, and loaded in tandem
onto (ii) lentil lectin-Sepharose (Sigma) to remove MMP9 and ﬁbronectin, and (iii) a 1 ml gelatin-
Sepharose column to capture proMMP2. After elution using 10% dimethyl sulfoxide (gelatin-
Sepharose column only), fractions containing proMMP2 were pooled and dialyzed into MES buffer.
2.1.4. ProMMP3
Recombinant C-terminally FLAG-tagged human proMMP3 was expressed from pGW1HG in CHO-
K1 cells and puriﬁed from supernatants in MES buffer using a (i) Green-agarose (Sigma) column. After
elution with 1 M NaCl, eluates were loaded on a (ii) Zn2þ-chelating column (Amersham Biosciences)
and chromatographed with an imidazole gradient. Fractions containing proMMP3 were pooled,
dialyzed into Tris-buffered saline (TBS; 50 mM Tris, 150 mM NaCl, pH 7.4), and subsequently loaded
onto an (iii) anti-FLAG-agarose column (Sigma). After elution with 100 mM glycine, pH 3.5, fractions
were immediately adjusted to pH 7–8 using 1 M Tris pH 8.0, and fractions containing proMMP3 were
pooled and dialyzed into HEPES buffer.
2.1.5. ProMMP8
CHO-K1 cells were transfected with pGW1HG-MMP8 and selected using 25 μg/ml mycophenolic
acid (Invitrogen); conditioned medium was collected from roller bottles. To remove gelatinases
(MMP2 and MMP9), culture supernatants were chromatographed over (i) gelatin-Sepharose 4B resin
(Amersham Biosciences) connected in tandem with (ii) a Red-Sepharose CL-6B column (Amersham
Biosciences). MMP8 was eluted from Red-Sepharose with 1 M NaCl in TBS, and (iii) loaded on a
column of Zn2þ-chelating Sepharose resin (Amersham Biosciences). Fractions containing MMP-8
were pooled and chromatographed over (iv) lentil lectin-agarose-Sepharose 4B (Sigma-Aldrich) and
eluted with 100 mm α-D-methylmannopyranoside (Sigma) in TBS. Puriﬁed proMMP8 was buffer
exchanged into collagenase assay buffer (50 mM Tris, 200 mM NaCl, 5 mM CaCl2, 0.05% Brij-35, pH
7.4) using a PD-10 Sephadex G-25 column (Amersham Biosciences).
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Human MMP9 was expressed from pGW1HG in CHO-K1 cells with 25 μg/ml mycophenolic acid for
selection. ProMMP9 was captured from conditioned medium on a gelatin-Sepharose column
(Amersham Biosciences) in MES buffer, and eluted after extensive washing in MES buffer supple-
mented with 10% dimethyl sulfoxide. ProMMP-9 was dialyzed into HEPES buffer.
2.1.7. ProMMP13
Recombinant C-terminally FLAG-tagged human MMP13 was expressed in CHO-K1 cells from
pGW1HG and puriﬁed from culture supernatants using a (i) green-agarose column (Sigma). After
extensive washing with MES buffer, bound protein was eluted using 1 M NaCl, and fractions con-
taining MMP-13 were dialyzed into TBS. MMP13 was then puriﬁed to homogeneity using an (ii) anti-
FLAG-agarose column (Sigma). After elution with 100 mM glycine (pH 3.5), fractions were immedi-
ately adjusted to pH 7–8 using 1 M Tris pH 8.0. ProMMP13 was dialyzed into HEPES buffer.
2.1.8. ProMMP14
Soluble MT1-MMP with a FLAG tag in place of the transmembrane and cytoplasmic domains was
cloned into pPIC9 (Invitrogen) and expressed in Pichia GS115 cells (Invitrogen). Cells were grown in
500 ml bafﬂed ﬂasks. After 24 h, 0.5% methanol was added to induce recombinant protein expression.
Culture medium was diluted in MES buffer and MT1-MMP was puriﬁed using a red agarose column
(Sigma). After extensive washing with MES buffer, protein was eluted with 1 M NaCl, and fractions
containing proMMP14 were pooled and dialyzed into HEPES buffer.3. PICS peptide library preparation.
Human whole proteome-derived peptide libraries for MMP speciﬁcity proﬁling were prepared as
described in great detail in Nature Protocols [9]: in brief, cell pellets were collected from human
lymphoblast cell K562 cultures and lysed in 20 mM HEPES (pH 7.5) supplemented with 0.1% (w/v)
SDS and protease inhibitors to prevent unwanted proteolysis (1Roche cOmplete plus 1 mM PMSF
and 10 mM EDTA). Cell debris was removed by centrifugation (26,000g, 1 h, 4 °C); soluble proteins
were denatured using guanidine hydrochloride (4 M), and cysteine side-chains were reduced with
20 mM DTT (1 h, 37 °C). Free sulfhydryl groups were protected with 40 mM iodoacetamide (3 h,
20 °C) to avoid peptide crosslinking and reactions were stopped by adding more DTT (5 mM, 15 min,
20 °C). Reaction clean-up was performed using chloroform/methanol precipitation as described
elsewhere [48], pellets were air-dried and re-suspended in 100 mM HEPES, 5 mM CaCl2, pH 7.5, and
digested with TPCK-treated trypsin or GluC (Staphylococcus aureus protease V8, Worthington) at a
protease to proteome ratio of 1:100 (w/w) overnight at 37 °C. Note, another protease often used for
PICS library preparation is chymotrypsin. After inactivation of trypsin/GluC with 1 mM PMSF (30 min,
20 °C), undigested protein aggregates were removed by centrifugation (20,000g, 10 min, 4 °C). Pri-
mary amines of peptide N-termini (α-amines) and lysine side chains (ε-amines) were blocked by
reductive dimethylation with 30 mM formaldehyde (CH2O) and 15 mM sodium cyanoborohydride
(NaCNBH3, Sterogene) at 20 °C for 16 h overnight (pH 6–7). To ensure completeness of amine
blocking, another 15 mM formaldehyde and 15 mM sodium cyanoborohydride were added and
incubated for additional two hours. Samples were desalted by size exclusion chromatography using
Sephadex G-10 columns (10 mM potassium phosphate buffer, pH 2.7, 10% (v/v) methanol), and after
methanol removal by vacuum concentration (SpeedVac, Thermo), peptides were puriﬁed by reversed-
phase chromatography on an ÄKTA™ high-performance liquid chromatography system (Äkta
Explorer, GE Healthcare) using a RESOURCE RPC column (GE Healthcare); wash buffer contained 0.3%
(v/v) formic acid, and samples were eluted in 80% (v/v) acetonitrile, both in HPLC-grade H2O. These
PICS peptide libraries were concentrated by rotary evaporation under vacuum, re-suspended in water,
and stored in 200–400 mg aliquots of 5–15 mg/ml at 80 °C until use. Peptide concentration was
estimated using the bicinchoninic assay (BCA, Pierce). All reagents were purchased from Sigma-
Aldrich unless otherwise speciﬁed.
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MMP cleavage assays were performed by incubation of 200–400 mg human whole-proteome
peptide library with active recombinant MMP at a protease to peptide library ratio of 1:100 (w/w) in
50 mM HEPES, 150 mM NaCl, 5 mM CaCl2 at pH 7.4, overnight, and stopped by heat inactivation at
70 °C for 30 min. Prime-side cleavage products generated by MMP cleavage were subsequently iso-
lated by positive enrichment using the biotin handle. In short, cleaved peptides with a free primary
amine at the N-terminus generated by MMP activity were biotinylated by incubation with 0.5 mM
Sulfo-NHS-SS-Biotin, an amine-reactive biotin with a redox-sensitive and thus cleavable disulﬁde
linker (Thermo Scientiﬁc) for 2 h at 20 °C. Biotinylated prime-side cleavage products were separated
from uncleaved peptides by afﬁnity puriﬁcation, incubating with 300 μl Streptavidin Sepharose slurry
(GE Healthcare) for 2 h with mild agitation. After extensive washing (50 mM HEPES, pH 7.2), bioti-
nylated peptides were eluted with 20 mM DTT (2 h, 20 °C), desalted using reversed-phase solid phase
extraction (Sep-Pak C18, Waters) with binding and washing in 0.1% (v/v) formic acid and elution in
80% (v/v) acetonitrile, both in HPLC-grade H2O. Eluates were vacuum dried to near dryness using a
SpeedVac concentrator (Thermo), brought to 10 μl with 0.1% formic acid, and stored at 80 °C until
LC–MS/MS analysis.5. LC–MS/MS, peptide spectrum matching, and data analysis
LC-MS/MS analysis was performed using an LC Packings capillary LC system (Dionex) coupled
online to a quadrupole time-of-ﬂight mass spectrometer operated either by the UBC Center for Blood
Research Mass Spectrometry Suite (QSTAR XL; Applied Biosystems), or by the UBC Proteomics Core
Facility (QSTAR Pulsar I, Applied Biosystems). Samples were diluted in 0.3% (v/v) formic acid and
loaded onto a column packed with Magic C18 resin (Michrom Bioresources). Peptides were eluted
using a 2–80% (v/v) acetonitrile gradient in 0.1% (v/v) formic acid over 95 min. MS/MS data were
acquired automatically, using Analyst QS software, v1.1 (Applied Biosystems) for data-dependent
acquisition based on a 1 s MS survey scan from 350 m/z to 1500 m/z, followed by up to 3 MS/MS scans
of 2 s each. Single charged ions were excluded because in ESI mode, peptides typically carry multiple
charges. Centroids were calculated for the acquired data that was converted to mzXML format using
msConvert [49]. Peptides were identiﬁed from the human UniProtKB/SwissProt database containing
canonical and isoform protein sequences (downloaded October 2013) using the search engine X!
Tandem [2] in conjunction with PeptideProphet [11], both implemented in the Trans Proteomic
Pipeline v4.3 [10], at an estimated false discovery rate (FDR) of 1%. Search parameters included a mass
tolerance of 200 ppm for parental ions and 0.2 Da (Da) for fragment ions, allowing up to two missed
cleavages. The following ﬁxed peptide modiﬁcations were set: carbamidomethylation of cysteine side
chains (þ57.02 Da) and dimethylation of lysine Ɛ-amines (þ28.03 Da); methionine oxidation
(þ15.99 Da). N-terminal dimethylation (þ28.03 Da) and thioacylation (þ88.00 Da) were set as
variables. Note, N-terminally thioacylated peptides identiﬁed by LC–MS/MS represent prime-side
cleavage products of the proteases of interest. The complete cleavage sites were reconstructed
bioinformatically using the open web-based program WebPICS [12], available at http://clipserve.clip.
ubc.ca/pics/, which generates a non-redundant list of identiﬁed cleavage sites by matching each prime
side peptide sequence to the human IPI database (v3.69, 174784 entries; EMBL-EBI, UK) and extracting
the non-prime cleavage side sequence up to the next cleavage site of the enzyme used for library
generation, i.e. to the next N-terminal Asp or Glu for GluC-libraries, or the next N-terminal Arg or Lys
in the case of trypsin-generated libraries. Subsite positions with ambiguous information coming e.g.
from different protein isoforms are omitted and replaced by X for further analysis. Identiﬁed cleavage
sites can be summarized as heat maps, by using e.g. Gnuplot (www.gnuplot.info), or iceLogos (http://
iomics.ugent.be/icelogoserver/index.html) [29]
U. Eckhard et al. / Data in Brief 7 (2016) 299–3103086. Quenched ﬂuorescence protease activity assay
Synthetic quenched ﬂuorescent (QF) peptides were purchased from ChinaPeptides Co. Ltd.
(Shanghai, China), dissolved in DMSO and protected from light. Working stocks (100 μM) were pre-
pared in DMSO using the molar extinction coefﬁcient of the conjugated quencher (DNP; (2,4)-dini-
trophenyl) of 6.985 cm1mM1 at 400 nm [50]. MMP zymogens (MMP1, MMP2, MMP8, MMP9,
MMP14) were activated in 100 mM Tris, pH 7.5, 100 mM NaCl, 10 mM CaCl2, and 0.05% Brij-35, using
1 mM APMA (para-aminophenylmercuric acetate) at 37 °C for 30 min. Chymotrypsin was used to
activate MMP3 at a ratio of 1:100 (w/w) for 30 min at 37 °C, and was subsequently inactivated using
1 mM PMSF. MMP7, MMP12, and MMP13 were typically auto-activated during puriﬁcation. Quenched
ﬂuorescent peptide assays were performed immediately after MMP activation in the presence of
protease inhibitor cocktail (HALT™, Life Technologies, no EDTA added) using a multi-wavelength
ﬂuorescence scanner (POLARstar OPTIMA, BMG Labtech). Each MMP (1–10 nM) was incubated with
1 mM QF-peptide in 100 mL of 100 mM Tris, pH 7.5, 100 mM NaCl, 10 mM CaCl2, and 0.05% Brij-35, and
the increase in ﬂuorescence was measured at 45 s intervals for 1 h at 37 °C. The excitation and
emission wavelengths were set to 320 and 405 nm, respectively, and all measurements were per-
formed in duplicate. Experiments were repeated three times with independent substrate and MMP
preparations on consecutive days.Acknowledgments
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